Fig. 2 | Signal Transduction and Targeted Therapy

Fig. 2

From: Gene replacement therapy in Bietti crystalline corneoretinal dystrophy: an open-label, single-arm, exploratory trial

Fig. 2

Best-corrected visual acuity (BCVA) changes from baseline in 11 participants. a–k Changes in early treatment of diabetic retinopathy study (ETDRS) chart letters from baseline at each study visit for participants R001 (a) and R003–R012 (b–k). l Average changes in the BCVA of the treated and untreated eyes from baseline of the 11 participants, excluding the BCVA data during the cataract period (D1-D180) for participant R005. At each visit, the number of treated eyes (n) with BCVA values is shown below the x-axis. Owing to the COVID-19 pandemic or poor compliance, some participants were unable to participate in the scheduled follow-up, resulting in changes in the number of treated eyes at each follow-up time. *p < 0.05. Data are presented as mean ± SD. BL baseline. Participants R001 and R003 were infected with COVID-19 after 1 year postoperatively, therefore, the arrows point lateral to the x-axis

Back to article page